OC treatments were administered in this study either alone, or after completing presurgical (neoadjuvant) regimens with the dual EGFR–HER2 inhibitor lapatinib (LP), in a test system intended to model HER2-positive BC. The gene discussed is EGFR; the disease is breast cancer.